- Phase 2 clinical trial for OXE103 for the treatment of concussion is conducted at the University of Kansas Medical Center, Kansas City, Kansas
- Sign up highly symptomatic participants within 28 days of injury
- Promisingintermediate Results show potential for OXE103 as an effective treatment for concussion
- There are currently no effective pharmacological FDA-approved treatments for: concussion
- First-in-class investigational drug to treat potential underlying neuro-metabolic and axonal damage in concussion
Boston, Mass., Aug. 3, 2022 (GLOBE NEWSWIRE) — Oxeia Biopharmaceuticals Inc., a clinical-stage biotech company developing a drug therapy for concussion to address underlying neuro-metabolic dysfunction and axonal injury, today announced the completion of a interim analysis of the ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center.
The interim results suggest a potentially effective treatment for concussion. The trial is aimed at treating subjects within 28 days of injury who are highly symptomatic at screening. This group represents the majority of concussion patients who are not treated immediately after their injury.
According to Oxeia’s CEO, Dr. Michael Wyand, “I am encouraged by the interim results we are seeing from the trial. The interim data offers hope of an effective treatment for the millions of people who suffer from persistent post-concussion symptoms due to a lack of effective treatment options.”
“An effective therapy for these persistently symptomatic patients would be an important step forward,” said Michael Rippee, MD, an associate professor of neurology at the University of Kansas Medical Center and principal investigator on the study.
Once full topline data is available, full data results will be presented at a medical conference.
# # #
ABOUT THE TRIAL
The trial enrolls participants within 28 days of injury who are highly symptomatic at screening. The aim of this phase 2 study is to reduce the symptom burden with OXE103 treatment. Measures of cognition and balance are also followed to provide an objective assessment of recovery. Those interested in participating should visit: www.restisnotenough.com
OXE103 is synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier and is now being tested in humans to potentially treat concussions by addressing underlying neuro-metabolic dysfunction and axonal injury. OXE103 uniquely targets the hippocampal region of the brain, an area important for cognition and memory. Treatment with OXE103 has been shown in numerous animal and laboratory studies to restore normal energy metabolism, increase appetite and reduce the toxic effects of reactive oxygen species that form in low energy states.
About the University of Kansas medical Centre
The mission of the University of Kansas Medical Center is to train exceptional healthcare professionals through a full suite of undergraduate, graduate, professional, postgraduate, and teaching programs in the schools of medicine, nursing, and health professions. KU Medical Center also advances the health sciences through world-class research programs; provides compassionate and state-of-the-art patient care in an academic medical center environment; and works with communities in every Kansas county to improve Kansas health.
About Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals, headquartered in Boston, MA, is a privately held, clinical-stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. For more information, visit: http://www.oxeiabiopharma.com/
The content is from GlobeNewswire. DKODING Media is not responsible for the content offered or any links related to this content. DKODING Media is not responsible for the accuracy, timeliness or quality of the content.